Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Qiagen NV QGEN

Technology Scientific & Technical Instruments
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic... see more

Recent & Breaking News (NYSE:QGEN)

QIAGEN's QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation

Business Wire May 21, 2019

QIAGEN Gains 510(k) Clearance by FDA for QIAstat-Dx in the U.S. and Launches System as Next Generation Platform for Syndromic Insights

Business Wire May 20, 2019

QIAGEN and Inovio Collaborate to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions

Business Wire May 16, 2019

Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

PR Newswire May 16, 2019

QIAGEN: Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase

Business Wire May 10, 2019

QIAGEN Reports Results for First Quarter of 2019 and Announces Plans for New $100 Million Share Repurchase Program

Business Wire May 6, 2019

QIAGEN Posts 2018 Annual Report on Its Website

Business Wire May 3, 2019

QIAGEN N.V. to Report First Quarter 2019 Results

Business Wire April 15, 2019

QIAGEN Launches First FDA-Approved Companion Diagnostic Using FGFR Alterations to Help Guide the Treatment of Metastatic Urothelial Cancer

Business Wire April 12, 2019

QIAGEN’s QuantiFERON®-TB Passes Milestone of 60 Million Tests in Global Fight against Tuberculosis, Current Annual Run Rate Exceeds 12 Million Tests

Business Wire April 11, 2019

QIAGEN and NeuMoDx expand assay menu for their next generation of fully integrated PCR systems for clinical laboratories in Europe and also announce availability of NeuMoDx 96 version

Business Wire April 11, 2019

QIAGEN Highlights Profile of New QIAstat-Dx Meningitis / Encephalitis pAnel Focused on Most Prevalent Central Nervous System Pathogens

Business Wire April 11, 2019

QIAGEN and LabCorp Launch Collaboration to Provide Day-One Access for Patients to Innovative Companion Diagnostics at the Time of Drug Approvals

Business Wire April 3, 2019

QIAGEN Launches Novel Liquid Biopsy Solutions and NGS Panels with Seamlessly Integrated Bioinformatics to Support Advances in Cancer Research

Business Wire March 28, 2019

QIAGEN supports World TB Day with major innovations in the fight against latent tuberculosis

Business Wire March 24, 2019

QIAGEN and Tecan Announce Collaboration to Streamline Preanalytical Processing of QuantiFERON-TB Gold Plus

Business Wire March 8, 2019

QIAGEN Announces 20-F Annual Report Filing for 2018 Results

Business Wire March 6, 2019

QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens

Business Wire February 18, 2019

QIAGEN Reports Results for Fourth Quarter and Full-Year 2018

Business Wire February 4, 2019

QIAGEN Informatics Solutions Chosen to Support Genomics England’s Bold Five Million Genomes in Five Years Project

Business Wire February 4, 2019